Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Articles|November 18, 2026

Biocon’s Pebrilzo Becomes First Breast Cancer Treatment Biosimilar Approved Under EMA’s Tailored Clinical Approach

Listen
0:00 / 0:00

Key Takeaways

  • European Commission authorized Pebrilzo, a 420 mg pertuzumab biosimilar, marking the first EMA biosimilar approval using the tailored clinical approach and Biocon’s fifth oncology biosimilar in Europe and the US.
  • CHMP’s March 2026 reflection paper enables reliance on analytical and PK similarity to infer comparable safety and efficacy, deemphasizing comparative efficacy trials that often add little to biosimilarity determinations.
SHOW MORE

The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.

Biocon announced on November 18, 2026, that the European Commission (EC) granted marketing authorization for Pebrilzo, its biosimilar to Perjeta (pertuzumab), for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union.¹ Biocon said Pebrilzo is the first biosimilar authorized under the European Medicines Agency’s (EMA’s) new tailored clinical approach.¹

The EC decision follows the positive opinion from EMA’s Committee for Medicinal Products for Human Use (CHMP) that BioPharm International® reported in September, when Pebrilzo became the first monoclonal antibody biosimilar to receive a CHMP recommendation under the framework.

“The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon,” said Shreehas Tambe, chief executive officer and managing director of Biocon.¹ Tambe said pertuzumab becomes Biocon’s “fifth oncology biosimilar approved in both Europe and the United States.”¹

What is the tailored clinical approach?

CHMP adopted its “Reflection paper on a tailored clinical approach in biosimilar development” on March 16, 2026.² The paper examines settings in which similar clinical efficacy and safety of a biosimilar candidate and its reference product can be inferred from analytical and pharmacokinetic (PK) similarity, and it notes that comparative efficacy studies generally did not add pivotal information to biosimilarity assessments.²

Under the previous standard, developers were typically expected to run comparative efficacy studies to confirm similar clinical performance. The new approach indicates that such studies will no longer be expected for most biosimilar candidates.³ BioPharm International covered EMA’s proposal when the draft reflection paper was released, and FDA has signaled a similar shift through October 2025 draft guidance proposing that comparative efficacy studies may not be needed in some cases.

For Pebrilzo, Biocon said extensive analytical characterization and comparative clinical PK data showed the product is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.¹

The shift places more weight on the comparability work done during development. In a Q&A with BioPharm International, Zara Bukhari, a PhD scholar at the University of the Pacific, said, “Process development for biosimilars differs from other biologics and small-molecule drugs primarily due to the need to demonstrate high similarity to an existing reference product.”

What is Pebrilzo approved for?

“The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon.” Shreehas Tambe, chief executive officer and managing director, Biocon

Pebrilzo is a 420 mg concentrate for solution for infusion used in combination regimens for HER2-positive breast cancer treatment. In the EU, Pebrilzo is authorized with trastuzumab and chemotherapy as neoadjuvant treatment for adults with high-risk, HER2-positive locally advanced, inflammatory, or early-stage breast cancer and as adjuvant treatment for adults with high-risk, HER2-positive early breast cancer.¹ It is also authorized with trastuzumab and docetaxel for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.¹

Biocon noted that about 15% to 20% of invasive breast cancers involve HER2 overexpression or amplification.¹

Where does Pebrilzo stand in the US?

FDA approved Pebrilzo (pertuzumab-qcay) as a biosimilar to Perjeta on November 16, 2026.⁴ Biocon also announced a global settlement and license agreement with Genentech that secures the earliest licensed US launch date for Pebrilzo in the third quarter of calendar year 2028.⁴

What happens next?

Biocon has not disclosed European launch timing. As the first biosimilar approval under the tailored pathway, Pebrilzo is likely to be watched as a test case by other biosimilar developers weighing whether to skip comparative efficacy studies for their own EU filings.

References

  1. Biocon’s pertuzumab gets marketing authorization in EU, first biosimilar approved under new tailored clinical approach. News release. Biocon; November 18, 2026. Accessed November 18, 2026.
  2. European Medicines Agency. Reflection paper on a tailored clinical approach in biosimilar development. Adopted March 16, 2026. Accessed November 18, 2026.
  3. EMA adopts landmark reflection paper on tailored clinical approach for biosimilars. GaBI Online. April 8, 2026. Accessed November 18, 2026.
  4. Biocon secures USFDA approval for Pebrilzo, eyes US launch in Q3 2028. Medical Dialogues. November 2026. Accessed November 18, 2026.

Related to this article